Tracleer Study First Ever to Show Benefits in Eisenmenger's Syndrome
12. Juli 2005 01:38 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, July 12, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that in the BREATHE-5 study evaluating the use of Tracleer(r) (bosentan) in pulmonary...
Actelion Ltd -- Newly Published Study Suggests Role for Clazosentan in the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Haemorrhage
04. Juli 2005 01:00 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, July 4, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) announced today that a study published in the July edition of the Journal of Neurosurgery suggests that clazosentan can...
Actelion Launches Tracleer in PAH in Japan
08. Juni 2005 01:00 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, June 8, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that Tracleer(r) (bosentan) is now available upon prescription to all patients in Japan....
Actelion Ltd: Long-Term Tracleer (bosentan) Safety Profile Confirmed with Completion of Non-Interventional Program in Almost 5,000 Patients
24. Mai 2005 01:22 ET
|
Actelion Ltd.
SAN DIEGO, May 24, 2005 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced that data from almost 5,000 Tracleer(R)-treated patients amounting to 3,416 patient-years of treatment were...
Actelion Provides Update on Palosuran in Diabetic Nephropathy
23. Mai 2005 01:23 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, May 23, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) announced today that preliminary efficacy data generated in the proof-of-concept program testing its urotensin-II receptor...
Actelion Announces First Quarter Results 2005
21. April 2005 01:18 ET
|
Actelion Ltd.
-- Total net revenue increases to CHF 146.4 million, up 45
percent compared to Q1 2004
-- Expanding PAH market results in strong Tracleer(r) sales
of CHF 139.8 million
-- Operating...
Annual General Meeting of the Shareholders in Basel, Switzerland
14. April 2005 11:21 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland , April 14, 2005 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd (SWX:ATLN), shareholders approved the following resolutions:
-- Increase of the...
Actelion Ltd: Japanese Approval for Tracleer(r) in PAH
11. April 2005 01:31 ET
|
Actelion Ltd.
ALLSCHWIL, Switerzerland, April 11, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that the Japanese Ministry of Health, Labor and Welfare has granted formal approval...
Renin Alliance of Actelion and Merck & Co., Inc. Achieves Second Milestone
15. März 2005 01:00 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, March 15, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that the renin alliance with Merck & Co., Inc., (NYSE:MRK) has achieved its second...
Actelion Provides Update on Bosentan in Japan
28. Februar 2005 01:00 ET
|
Actelion Ltd.
-- Formal approval expected in early April
-- Market introduction foreseen for spring 2005
ALLSCHWIL, Switzerland, Feb. 28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced that is...